PharmaDrug Advances PD-001 in Fight Against Viral Diseases
Company Announcements

PharmaDrug Advances PD-001 in Fight Against Viral Diseases

Story Highlights

Pharmadrug (TSE:PHRX) has released an update.

PharmaDrug Inc., through its subsidiary Sairiyo Therapeutics, is advancing the clinical development of PD-001, a patented reformulated version of Cepharanthine, aimed at treating a range of viral infectious diseases. After receiving ethics approval in Australia, the company is embarking on a Phase 1 clinical study, with hopes of progressing towards FDA approval. PD-001 is noted for its potential in combating viruses like Ebola and COVID-19, due to its enhanced bioavailability compared to existing formulations.

For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPharmaDrug Debenture Units Issuance Announcement
TipRanks Canadian Auto-Generated NewsdeskPharmaDrug Advances PD-001 for Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskPharmaDrug Begins Clinical Trial for Infectious Disease Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App